Janux Therapeutics, Inc. (JANX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	24.0M	10.0M	10.6M	8.1M	8.6M
Cost of Revenue	—	2.0M	2.1M	2.0M	841.0K
Gross Profit	24.0M	8.0M	8.5M	6.1M	7.8M
Operating Expenses
R&D Expense	124.0M	125.9M	68.4M	54.9M	53.4M
SG&A Expense	43.6M	41.8M	41.0M	26.1M	22.3M
General & Admin Expense	43.6M	41.8M	41.0M	26.1M	22.3M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	(2.0M)	(2.1M)	(2.0M)	(841.0K)
Total Operating Expenses	167.6M	165.6M	107.4M	79.1M	74.9M
Cost and Expenses	167.6M	167.7M	109.4M	81.1M	75.7M
Operating Income (EBIT)	(143.6M)	(157.7M)	(98.8M)	(73.0M)	(67.1M)
Non-Operating
Interest Income	41.0M	44.0M	29.9M	14.7M	4.0M
Interest Expense	—	—	—	—	—
Net Interest Income	41.0M	44.0M	29.9M	14.7M	4.0M
Other Non-Op Income/Expense	41.0M	44.0M	29.9M	14.7M	4.0M
Non-Operating Income (excl Interest)	(41.0M)	(44.0M)	(29.9M)	(14.7M)	(4.0M)
EBT (Pre-Tax Income)	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Earnings from Cont. Ops	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)
Per Share
Basic EPS	($1.65)	($1.83)	($1.28)	($1.32)	($1.52)
Diluted EPS	($1.65)	($1.83)	($1.28)	($1.32)	($1.52)
Revenue Per Share	$0.38	$0.16	$0.20	$0.18	$0.21
Shares
Basic Shares Outstanding	62.9M	62.0M	53.8M	44.0M	41.5M
Diluted Shares Outstanding	62.9M	62.0M	53.8M	44.0M	41.5M
Profitability Metrics
EBITDA	(100.7M)	(111.6M)	(66.9M)	(56.3M)	(62.2M)
D&A	1.9M	2.0M	2.1M	2.0M	841.0K
EBIT	(102.6M)	(113.6M)	(69.0M)	(58.3M)	(63.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026